Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.

Cho BC, Dy GK, Govindan R, Kim DW, Pennell NA, Zalcman G, Besse B, Kim JH, Koca G, Rajagopalan P, Langer S, Ocker M, Nogai H, Barlesi F.

Lung Cancer. 2018 Sep;123:14-21. doi: 10.1016/j.lungcan.2018.04.022. Epub 2018 Apr 27.

2.

Sensitive Detection of Exosomal Proteins via a Compact Surface Plasmon Resonance Biosensor for Cancer Diagnosis.

Liu C, Zeng X, An Z, Yang Y, Eisenbaum M, Gu X, Jornet JM, Dy GK, Reid ME, Gan Q, Wu Y.

ACS Sens. 2018 Jul 31. doi: 10.1021/acssensors.8b00230. [Epub ahead of print]

PMID:
30019892
3.

Concomitant Mediastinoscopy Increases the Risk of Postoperative Pneumonia After Pulmonary Lobectomy.

Yendamuri S, Battoo A, Attwood K, Dhillon SS, Dy GK, Hennon M, Picone A, Nwogu C, Demmy T, Dexter E.

Ann Surg Oncol. 2018 May;25(5):1269-1276. doi: 10.1245/s10434-018-6397-6. Epub 2018 Feb 27.

PMID:
29488189
4.

Risk and benefit of neoadjuvant therapy among patients undergoing resection for non-small-cell lung cancer.

Yendamuri S, Groman A, Miller A, Demmy T, Hennon M, Dexter E, Picone A, Nwogu C, Dy GK.

Eur J Cardiothorac Surg. 2018 Mar 1;53(3):656-663. doi: 10.1093/ejcts/ezx406.

PMID:
29253122
5.

Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database.

Naqash AR, Stroud CRG, Butt MU, Dy GK, Hegde A, Muzaffar M, Yang LV, Hafiz M, Cherry CR, Walker PR.

Acta Oncol. 2018 Jun;57(6):867-872. doi: 10.1080/0284186X.2017.1415460. Epub 2017 Dec 15. No abstract available.

PMID:
29241410
6.

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.

Soria JC, Adjei AA, Bahleda R, Besse B, Ferte C, Planchard D, Zhou J, Ware J, Morrissey K, Shankar G, Lin W, Schutzman JL, Dy GK, Groen HJM.

Eur J Cancer. 2017 Nov;86:186-196. doi: 10.1016/j.ejca.2017.08.027. Epub 2017 Oct 6.

PMID:
28992562
7.

Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events.

Anwar S, Tan W, Hong CC, Admane S, Dozier A, Siedlecki F, Whitworth A, DiRaddo AM, DePaolo D, Jacob SM, Ma WW, Miller A, Adjei AA, Dy GK.

Cancers (Basel). 2017 Jun 26;9(7). pii: E73. doi: 10.3390/cancers9070073.

8.

Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.

Bahleda R, Grilley-Olson JE, Govindan R, Barlesi F, Greillier L, Perol M, Ray-Coquard I, Strumberg D, Schultheis B, Dy GK, Zalcman G, Weiss GJ, Walter AO, Kornacker M, Rajagopalan P, Henderson D, Nogai H, Ocker M, Soria JC.

Br J Cancer. 2017 Jun 6;116(12):1505-1512. doi: 10.1038/bjc.2017.92. Epub 2017 May 2.

9.

P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets): Track: Immunotherapy.

Goldman JW, Crino L, Vokes EE, Holgado E, Reckamp K, Pluzanski A, Spigel D, Kohlhaeufl M, Garassino M, Chow LQ, Gettinger S, Gerber DE, Havel L, Ramalingam SS, Dy GK, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Lopes G.

J Thorac Oncol. 2016 Oct;11(10S):S238-S239. doi: 10.1016/j.jtho.2016.08.107. Epub 2016 Sep 22. No abstract available.

10.

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.

Adjei AA, LoRusso P, Ribas A, Sosman JA, Pavlick A, Dy GK, Zhou X, Gangolli E, Kneissl M, Faucette S, Neuwirth R, Bózon V.

Invest New Drugs. 2017 Feb;35(1):47-58. doi: 10.1007/s10637-016-0391-2. Epub 2016 Sep 21.

11.

Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.

Zhang H, Shao H, Golubovskaya VM, Chen H, Cance W, Adjei AA, Dy GK.

Br J Cancer. 2016 Jul 12;115(2):203-11. doi: 10.1038/bjc.2016.190. Epub 2016 Jun 23.

12.

Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options.

Desai A, Menon SP, Dy GK.

Cancer Biol Med. 2016 Mar;13(1):77-86. doi: 10.28092/j.issn.2095-3941.2016.0008.

13.

First-line treatment of advanced ALK-positive non-small-cell lung cancer.

Gandhi S, Chen H, Zhao Y, Dy GK.

Lung Cancer (Auckl). 2015 Sep 18;6:71-82. doi: 10.2147/LCTT.S63491. eCollection 2015. Review.

14.

Pneumonectomy-Sparing NSAID Therapy for Pulmonary Inflammatory Myofibroblastic Tumor.

Ghani S, Desai A, Pokharel S, Demmy T, Dy GK.

J Thorac Oncol. 2015 Sep;10(9):e89-e90. doi: 10.1097/JTO.0000000000000574. No abstract available.

15.

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.

Vansteenkiste JF, Canon JL, De Braud F, Grossi F, De Pas T, Gray JE, Su WC, Felip E, Yoshioka H, Gridelli C, Dy GK, Thongprasert S, Reck M, Aimone P, Vidam GA, Roussou P, Wang YA, Di Tomaso E, Soria JC.

J Thorac Oncol. 2015 Sep;10(9):1319-1327. doi: 10.1097/JTO.0000000000000607.

16.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS.

Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9. Epub 2015 Feb 20.

17.

Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors.

Infante JR, Benhadji KA, Dy GK, Fetterly G, Ma WW, Bendell J, Callies S, Adjei AA.

Invest New Drugs. 2015 Apr;33(2):432-9. doi: 10.1007/s10637-015-0207-9. Epub 2015 Feb 3.

PMID:
25640850
18.

A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.

Ngamphaiboon N, Dy GK, Ma WW, Zhao Y, Reungwetwattana T, DePaolo D, Ding Y, Brady W, Fetterly G, Adjei AA.

Invest New Drugs. 2015 Feb;33(1):225-32. doi: 10.1007/s10637-014-0174-6. Epub 2014 Nov 5.

PMID:
25371323
19.

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.

Puzanov I, Sosman J, Santoro A, Saif MW, Goff L, Dy GK, Zucali P, Means-Powell JA, Ma WW, Simonelli M, Martell R, Chai F, Lamar M, Savage RE, Schwartz B, Adjei AA.

Invest New Drugs. 2015 Feb;33(1):159-68. doi: 10.1007/s10637-014-0167-5. Epub 2014 Oct 8.

20.

NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status.

Dy GK, Molina JR, Qi Y, Ansari R, Thomas S, Ross HJ, Soori G, Anderson D, Aubry MC, Meyers J, Adjei AA, Mandrekar S, Adjei AA.

J Thorac Oncol. 2014 Aug;9(8):1146-53. doi: 10.1097/JTO.0000000000000217.

21.

The prognostic significance of focal adhesion kinase expression in stage I non-small-cell lung cancer.

Dy GK, Ylagan L, Pokharel S, Miller A, Brese E, Bshara W, Morrison C, Cance WG, Golubovskaya VM.

J Thorac Oncol. 2014 Sep;9(9):1278-84. doi: 10.1097/JTO.0000000000000248.

22.

Targeted therapies in development for non-small cell lung cancer.

Reungwetwattana T, Dy GK.

J Carcinog. 2013 Dec 31;12:22. doi: 10.4103/1477-3163.123972. eCollection 2013. Review.

23.

Complementary and alternative medicine use among patients with thoracic malignancies.

Bismark RS, Chen H, Dy GK, Gage-Bouchard EA, Mahoney MC.

Support Care Cancer. 2014 Jul;22(7):1857-66. doi: 10.1007/s00520-014-2144-0. Epub 2014 Feb 21.

PMID:
24554203
24.

Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non-small-cell lung cancer.

Dy GK, Bogner PN, Tan W, Demmy TL, Farooq A, Chen H, Yendamuri SS, Nwogu CE, Bushunow PW, Gannon J, Adjei AA, Adjei AA, Ramnath N.

J Thorac Oncol. 2014 Feb;9(2):222-30. doi: 10.1097/JTO.0000000000000062.

25.

First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel.

Gupta N, Hatoum H, Dy GK.

Int J Nanomedicine. 2014;9:209-21. doi: 10.2147/IJN.S41770. Epub 2013 Dec 24. Review.

26.

Understanding, recognizing, and managing toxicities of targeted anticancer therapies.

Dy GK, Adjei AA.

CA Cancer J Clin. 2013 Jul-Aug;63(4):249-79. doi: 10.3322/caac.21184. Epub 2013 May 28. Review.

27.

A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.

Chow LQ, Jonker DI, Dy GK, Nicholas G, Fortin C, Patricia D, Adjei AA, Belani CP, Gupta A, Park JS, Zhang S, Sbar EI, Laurie SA.

Cancer Chemother Pharmacol. 2013 May;71(5):1273-85. doi: 10.1007/s00280-013-2126-9. Epub 2013 Mar 7.

PMID:
23468081
28.

A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer.

Ramnath N, Daignault-Newton S, Dy GK, Muindi JR, Adjei A, Elingrod VL, Kalemkerian GP, Cease KB, Stella PJ, Brenner DE, Troeschel S, Johnson CS, Trump DL.

Cancer Chemother Pharmacol. 2013 May;71(5):1173-82. doi: 10.1007/s00280-013-2109-x. Epub 2013 Feb 23.

29.

Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.

Weekes CD, Von Hoff DD, Adjei AA, Leffingwell DP, Eckhardt SG, Gore L, Lewis KD, Weiss GJ, Ramanathan RK, Dy GK, Ma WW, Sheedy B, Iverson C, Miner JN, Shen Z, Yeh LT, Dubowy RL, Jeffers M, Rajagopalan P, Clendeninn NJ.

Clin Cancer Res. 2013 Mar 1;19(5):1232-43. doi: 10.1158/1078-0432.CCR-12-3529. Epub 2013 Feb 22.

30.

A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.

Naing A, Cohen R, Dy GK, Hong DS, Dyster L, Hangauer DG, Kwan R, Fetterly G, Kurzrock R, Adjei AA.

Invest New Drugs. 2013 Aug;31(4):967-73. doi: 10.1007/s10637-013-9929-8. Epub 2013 Jan 30.

PMID:
23361621
31.

A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528.

Dy GK, Mandrekar SJ, Nelson GD, Meyers JP, Adjei AA, Ross HJ, Ansari RH, Lyss AP, Stella PJ, Schild SE, Molina JR, Adjei AA.

J Thorac Oncol. 2013 Jan;8(1):79-88. doi: 10.1097/JTO.0b013e318274a85d.

32.

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.

Infante JR, Novello S, Ma WW, Dy GK, Bendell JC, Huff A, Wang Q, Suttle AB, Allen R, Xu CF, Ottesen LH, Burris HA 3rd, Adjei AA.

Invest New Drugs. 2013 Aug;31(4):927-36. doi: 10.1007/s10637-012-9900-0. Epub 2012 Nov 22.

PMID:
23179337
33.

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.

Dy GK, Infante JR, Eckhardt SG, Novello S, Ma WW, Jones SF, Huff A, Wang Q, Suttle AB, Ottesen LH, Adjei AA, Burris HA 3rd.

Invest New Drugs. 2013 Aug;31(4):891-9. doi: 10.1007/s10637-012-9887-6. Epub 2012 Nov 8.

PMID:
23135778
34.

The role of focal adhesion kinase in lung cancer.

Dy GK.

Anticancer Agents Med Chem. 2013 May;13(4):581-3. Review.

PMID:
22934708
35.

Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.

Reungwetwattana T, Molina JR, Mandrekar SJ, Allen-Ziegler K, Rowland KM, Reuter NF, Luyun RF, Dy GK, Marks RS, Schild SE, Jett JR, Adjei AA.

J Thorac Oncol. 2012 May;7(5):919-22. doi: 10.1097/JTO.0b013e31824de0d6.

36.

Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.

Ma WW, Messersmith WA, Dy GK, Weekes CD, Whitworth A, Ren C, Maniar M, Wilhelm F, Eckhardt SG, Adjei AA, Jimeno A.

Clin Cancer Res. 2012 Apr 1;18(7):2048-55. doi: 10.1158/1078-0432.CCR-11-2813. Epub 2012 Feb 14.

37.

Investigational agents in metastatic basal cell carcinoma: focus on vismodegib.

Batty N, Kossoff E, Dy GK.

J Exp Pharmacol. 2012 Aug 30;4:97-103. doi: 10.2147/JEP.S26591. eCollection 2012. Review.

38.

Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.

Shao H, Gao C, Tang H, Zhang H, Roberts LR, Hylander BL, Repasky EA, Ma WW, Qiu J, Adjei AA, Dy GK, Yu C.

J Hepatol. 2012 Jan;56(1):176-83. doi: 10.1016/j.jhep.2011.07.013. Epub 2011 Aug 9.

PMID:
21835141
39.

Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer.

Shao H, Tang H, Salavaggione OE, Yu C, Hylander B, Tan W, Repasky E, Adjei AA, Dy GK.

J Thorac Oncol. 2011 Jun;6(6):998-1005. doi: 10.1097/JTO.0b013e318217b739.

40.

Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.

Schneider BJ, Gadgeel SM, Ramnath N, Wozniak AJ, Dy GK, Daignault S, Kalemkerian GP.

J Thorac Oncol. 2011 Jun;6(6):1117-20. doi: 10.1097/JTO.0b013e31821529c3.

41.

A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326.

Dy GK, Hillman SL, Rowland KM Jr, Molina JR, Steen PD, Wender DB, Nair S, Mandrekar S, Schild SE, Adjei AA; North Central Cancer Treatment Group Study N0326.

Cancer. 2010 Dec 15;116(24):5686-93. doi: 10.1002/cncr.25448.

42.

Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.

Adjei AA, Salavaggione OE, Mandrekar SJ, Dy GK, Ziegler KL, Endo C, Molina JR, Schild SE, Adjei AA.

J Thorac Oncol. 2010 Sep;5(9):1346-53. doi: 10.1097/JTO.0b013e3181ec18c4.

43.

Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.

Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR, Ziegler KL, Stella PJ, Rowland KM Jr, Schild SE, Zinner RG.

J Clin Oncol. 2010 Feb 1;28(4):614-9. doi: 10.1200/JCO.2009.23.6406. Epub 2009 Oct 19.

44.

Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144.

Dy GK, Hobday TJ, Nelson G, Windschitl HE, O'Connell MJ, Alberts SR, Goldberg RM, Nikcevich DA, Sargent DJ.

Clin Colorectal Cancer. 2009 Apr;8(2):88-93. Review.

45.

Thoracoscopic organ suffusion for regional lung chemotherapy (preliminary results).

Demmy TL, Tomaszewski G, Dy GK, Yendamuri S, Nwogu C, Pendyala L, Ramnath N, Adjei AA.

Ann Thorac Surg. 2009 Aug;88(2):385-90; discussion 390-1. doi: 10.1016/j.athoracsur.2009.04.101.

PMID:
19632379
46.

Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a north central cancer treatment group review of 3811 patients, n0144.

Dy GK, Hobday TJ, Nelson G, Windschitl HE, O'Connell MJ, Alberts SR, Goldberg RM, Nikcevich DA, Sargent DJ.

Clin Colorectal Cancer. 2009 Mar;8(2):88-93.

PMID:
19423501
47.

Emerging therapeutic targets in non-small cell lung cancer.

Dy GK, Adjei AA.

Proc Am Thorac Soc. 2009 Apr 15;6(2):218-23. doi: 10.1513/pats.200808-099LC. Review.

PMID:
19349491
48.

Systemic cancer therapy: evolution over the last 60 years.

Dy GK, Adjei AA.

Cancer. 2008 Oct 1;113(7 Suppl):1857-87. doi: 10.1002/cncr.23651. Review.

49.

BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.

Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN, Adjei AA.

Cancer Res. 2008 Aug 1;68(15):6145-53. doi: 10.1158/0008-5472.CAN-08-1430.

50.

Small cell lung cancer.

Sher T, Dy GK, Adjei AA.

Mayo Clin Proc. 2008 Mar;83(3):355-67. doi: 10.4065/83.3.355. Review.

PMID:
18316005

Supplemental Content

Support Center